Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
corporation entities : Incyte corporation save search
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
pipeline acquisition pharmaceuticals
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Incyte to Report First Quarter Financial Results - April 11, 2024
Published: 2024-04-11 (Crawled : 21:00) - biospace.com/
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.62%
H: 1.17%
C: -0.76%
first report financial results
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement china
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.12%
H: 0.3%
C: -2.29%
preclinical meeting
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.34%
H: 0.89%
C: 0.79%
meeting growing
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: 2.68%
H: 2.22%
C: -1.92%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
minjuvi brazil therapeutics
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.6%
H: 0.45%
C: 0.08%
MRUS | $40.75 0.74% 0.74% 570K
|
Health Technology
|
| O: 2.3%
H: 0.58%
C: -2.69%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
business year update financial results
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.95 -0.05% -0.05% 870K
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
Incyte to Present at Upcoming March 2024 Investor Conference
Published: 2024-02-15 (Crawled : 14:00) - biospace.com/
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.35%
H: 3.06%
C: 1.51%
conference
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -3.56%
H: 2.91%
C: -3.34%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: -0.4%
H: 0.23%
C: -0.46%
MGNX | $16.23 5.32% 5.05% 650K
|
Health Technology
|
| O: -5.25%
H: 2.94%
C: 2.18%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
financial
Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: -1.18%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 0.06%
H: 2.34%
C: 2.29%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.34%
H: 0.23%
C: -1.13%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 1.22%
H: 0.07%
C: -0.43%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.96%
H: 1.75%
C: 1.75%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: -1.15%
H: 1.03%
C: -1.5%
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
IPHA | $2.425 -7.02% 2.7K
|
Health Technology
|
| O: -3.1%
H: 1.2%
C: -0.8%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -3.72%
H: 0.58%
C: -3.82%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.26%
H: 0.73%
C: -0.36%
ARGX | $375.13 1.73% 1.7% 340K
|
Health Technology
|
| O: -2.3%
H: 1.65%
C: 0.83%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: -1.4%
expansion growth market
Anju Software Unveils Strategies for Data-Driven Decision-Making in Clinical Research at SCOPE Orlando 2024
Published: 2024-02-08 (Crawled : 16:00) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.02%
H: 0.65%
C: 0.02%
software research
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.65%
H: 0.57%
C: -3.21%
first management drug application china
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -1.55%
H: 2.76%
C: 1.84%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: 0.99%
H: 59.84%
C: 54.47%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.6%
H: 0.81%
C: 0.1%
monjuvi global commercialization
Innovent Announces Retirement of CFO and Appointment of New CFO
Published: 2024-02-05 (Crawled : 09:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.85%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.6%
H: 0.81%
C: 0.1%
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.